18 October 2012
An antibody that has already proven to put up a substantial fight against the skin condition psoriasis could have more widespread health benefits.
Research conducted at the University of California (UC) San Diego, School of Medicine has led to the suggestion that ustekinumab decreases the debilitating effects that Crohn's Disease can bring to a human body.
A form of inflammatory bowel disease, the condition can occur anywhere inside the body, though the most common area is in the intestines.
However, scientists at the American institute have demonstrated how the antibody ustekinumab can enhance the clinical response and remission of those suffering from moderate-to-severe Crohn's Disease.
Lead study author Dr William Sandborn, chief of the division of gastroenterology at the UC San Diego School of Medicine, pointed out: "Ustekinumab blocks two proteins that cause inflammation, interleukin 12 and 23.
"This finding is a significant first step towards a new treatment option for these patients."
He added that the institute will continue with its research into Crohn's Disease, with a goal "to increase clinical response and put the disease in remission to improve the patient's quality of life".
Posted by Edward Bartel
Health News is provided by Adfero in collaboration with Spire Healthcare. Please note that all copy above is ©Adfero Ltd. and does not reflect views or opinions of Spire Healthcare unless explicitly stated. Additional comments on the page from individual Spire consultants do not necessarily reflect the views or opinions of other consultants or Spire Healthcare.